New Research from the CWMH: No Increase in Major Malformations in Children with Prenatal Exposure to Olanzapine
No major malformations were associated with olanzapine exposure during the first trimester of pregnancy.
No major malformations were associated with olanzapine exposure during the first trimester of pregnancy.
Functional MRI revealed no differences in brain structure of white matter integrity in lithium-exposed versus non-lithium-exposed children born to mothers with bipolar spectrum disorder.
Diagnosis of a mood or anxiety disorder during pregnancy was associated with a 3.5-fold increase in adverse perinatal outcomes.
Two studies - one using neuropsychological assessments, another examining performance on standardized testing - show no association between prenatal antipsychotic exposure and neurodevelopmental outcomes.
Consistent with other studies, including a large meta-analysis, this study indicates no increased risk of ADHD in offspring following prenatal exposure to antidepressants.
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Largest studies to date demonstrate statistically significant risk of preterm birth among women with active PTSD.
The largest study to date observes no increase in risk of autism or ADHD in children with prenatal exposure to benzodiazepines.
Peer support interventions can reduce the incidence of postpartum depression and the severity of depressive symptoms.
Maternal ACEs were associated with both newborn amygdala volume and subsequent infant negative emotionality.